Updated: April 01, 2021 08:25 AM
Created: April 01, 2021 07:12 AM
ROCHESTER, N.Y. (WHEC)— Pfizer announced Thursday a trial of its COVID-19 vaccine shows it is effective for at least six months and is effective against a variant that first emerged in South Africa.
In a statement posted to its website, Pfizer, and its partner, BioNTech said the latest trial involved 12,000 people, and showed the vaccine to have a 91.3% vaccine efficacy against the virus. This was measured seven days through at least six months after the second dose. Pfizer reports no serious safety concerns were observed within that six-month period.
Additionally, it showed to be 100% effective against the variant, which drew early concerns that it could impact the vaccine's efficacy.
“These data confirm the favorable efficacy and safety profile of our vaccine and position us to submit a Biologics License Application to the U.S. FDA,” Pfizer's Chairman and Chief Executive Officer Albert Bourla said. “The high vaccine efficacy observed through up to six months following a second dose and against the variant prevalent in South Africa provides further confidence in our vaccine’s overall effectiveness.”
Copyright 2021 - WHEC-TV, LLC A Hubbard Broadcasting Company